HS Biopharm operates in the biopharmaceutical industry, focusing on the development and optimization of CHO (Chinese Hamster Ovary) cell lines for the production of therapeutic proteins and monoclonal antibodies. The company serves pharmaceutical and biotechnology clients who require high-quality cell lines for drug development and manufacturing. HS Biopharm's business model revolves around providing end-to-end solutions, from DNA transfection to commercial-scale production, ensuring high yield and quality. Revenue is generated through project-based contracts and long-term partnerships with clients. The company leverages advanced technologies and proprietary methodologies to optimize cell culture processes, including pH and temperature shifts, seed density adjustments, and bioreactor tuning. This approach allows for efficient and scalable production, meeting the stringent regulatory requirements of the biopharmaceutical market.

Keywords: CHO cell lines, therapeutic proteins, monoclonal antibodies, biopharmaceutical, cell culture, process optimization, DNA transfection, bioreactor tuning, pharmaceutical clients, biotechnology.